The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Huang, B ^a   Cohen, J R ^a   Fernando, R I ^a   Hamilton, D H ^a   Litzinger, M T ^a   Hodge, J W ^a   Palena, C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brachyury; CDKN1A; EMT; therapeutic resistance

Indexed keywords

BRACHYURY; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 1A; DOCETAXEL; LUCIFERASE; NAVELBINE; PROTEIN P21; RETINOBLASTOMA PROTEIN; T BOX TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL LEVEL; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIVITY; REPORTER GENE; SKIN TUMOR; TUMOR XENOGRAFT;

EID: 84879680963     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.208     Document Type: Article

References (42)

1. Edwards YH, Putt W, Lekoape KM, Stott D, Fox M, Hopkinson DA et al. The human homolog T of the mouse T(Brachyury) gene; gene structure, cDNA sequence, and assignment to chromosome 6q27. Genome Res 1996; 6: 226-233.
2. Kispert A, Herrmann BG. The Brachyury gene encodes a novel DNA binding protein. EMBO J 1993; 12: 3211-3220.
3. Kispert A, Koschorz B, Herrmann BG. The T protein encoded by Brachyury is a tissuespecific transcription factor. EMBO J 1995; 14: 4763-4772.
4. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cellmediated cancer immunotherapy. Clin Cancer Res 2007; 13: 2471-2478.
5. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C. Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol 2012; 39: 358-366.
6. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 2012; 18: 3868-3879.
7. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010; 120: 533-544.
8. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 2011; 71: 5296-5306.
9. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelialmesenchymal transition. Bioessays 2001; 23: 912-923.
10. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
11. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
12. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011; 27: 347-376.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
14. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 4147-4153.
15. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277-283.
16. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-5828.
17. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004; 18: 1131-1143.
18. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. Identification of selective inhibitors of cancer stemcells by high-throughput screening. Cell 2009; 138: 645-659.
19. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S et al. p21CIP1 attenuates Rasand c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009; 106: 19035-19039.
20. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004; 10: 1976-1983.
21. Ikeda K, Terashima M, Kawamura H, Takiyama I, Koeda K, Takagane A et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998; 28: 168-175.
22. Leveque D, Jehl F, Quoix E, Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol 1992; 32: 1096-1098.
23. Qiao X, Tullgren O, Lax I, Sirzen F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer (Amsterdam, The Netherlands) 2003; 41: 1-11.
24. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
25. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11: 847-862.
26. Kispert A, Herrmann BG, Leptin M, Reuter R. Homologs of the mouse Brachyury gene are involved in the specification of posterior terminal structures in Drosophila, Tribolium, and Locusta. Genes Dev 1994; 8: 2137-2150.
27. Behr R, Heneweer C, Viebahn C, Denker HW, Thie M. Epithelial-mesenchymal transition in colonies of rhesus monkey embryonic stem cells: a model for processes involved in gastrulation. Stem Cells 2005; 23: 805-816.
28. Vidricaire G, Jardine K, McBurney MW. Expression of the Brachyury gene during mesoderm development in differentiating embryonal carcinoma cell cultures. Development 1994; 120: 115-122.
29. Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells. Exp Biol Med (Maywood) 2011; 236: 537-545.
30. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059-2068.
31. Viebahn C, Stortz C, Mitchell SA, Blum M. Low proliferative and high migratory activity in the area of Brachyury expressing mesoderm progenitor cells in the gastrulating rabbit embryo. Development 2002; 129: 2355-2365.
32. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17: 323-334.
33. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004; 64: 8585-8594.
34. Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell 2007; 18: 4615-4624.
35. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 2004; 24: 8813-8822.
36. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
37. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-834.
38. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiationinduced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.
39. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
40. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
41. Du Z, Qin R, Wei C, Wang M, Shi C, Tian R et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in 'stem-cell-like' tumor cells. Dig Dis Sci 2011; 56: 741-750.
42. Sarkar D, Shields B, Davies ML, Muller J, Wakeman JA. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells. Int J Cancer 2011; 130: 328-337.